Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 9461402, 7 pages
https://doi.org/10.1155/2017/9461402
Research Article

Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy

1Sbarro Health Research Organization, Temple University, Philadelphia, PA, USA
2Unit of Radiation Oncology, University Hospital of Siena, Siena, Italy
3Department of Medicine, Surgery and Neurological Sciences, University of Siena, Siena, Italy
4Unit of Pathological Anatomy, Department of Medicine, Surgery and Neurological Sciences, University of Siena, Siena, Italy
5Unit of Neuroradiology, University Hospital of Siena, Siena, Italy

Correspondence should be addressed to Paolo Tini; ti.orebil@init-oloap

Received 6 June 2017; Accepted 9 August 2017; Published 12 October 2017

Academic Editor: Nader Pouratian

Copyright © 2017 Paolo Tini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Stupp, W. P. Mason, M. J. van den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. R. G. W. Verhaak, K. A. Hoadley, E. Purdom et al., “Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1,” Cancer Cell, vol. 17, no. 1, pp. 98–110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. C. W. Brennan, R. G. W. Verhaak, and A. McKenna, “The somatic genomic landscape of glioblastoma,” Cell, vol. 155, no. 2, pp. 462–477, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Tabatabai, M. Hegi, R. Stupp, and M. Weller, “Clinical implications of molecular neuropathology and biomarkers for malignant glioma,” Current Neurology and Neuroscience Reports, vol. 12, no. 3, pp. 302–307, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. E. Hegi, A.-C. Diserens, T. Gorlia et al., “MGMT gene silencing and benefit from temozolomide in glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 997–1003, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. Olson, P. K. Brastianos, and D. A. Palma, “Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: A systematic review and meta-analysis,” Journal of Neuro-Oncology, vol. 105, no. 2, pp. 325–335, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Stupp, M. E. Hegi, W. P. Mason et al., “Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial,” The Lancet Oncology, vol. 10, no. 5, pp. 459–466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. R. Gilbert, M. Wang, K. D. Aldape et al., “Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial,” Journal of Clinical Oncology, vol. 31, no. 32, pp. 4085–4091, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Pirtoli, G. Rubino, S. Marsili et al., “Three-dimensional conformal radiotherapy, temozolomide chemotherapy, and high-dose fractionated stereotactic boost in a protocol-driven, postoperative treatment schedule for high-grade gliomas,” TUMORI, vol. 95, no. 3, pp. 329–337, 2009. View at Google Scholar · View at Scopus
  10. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Tini, G. Belmonte, M. Toscano et al., “Combined epidermal growth factor receptor and beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma,” BioMed Research International, vol. 2015, Article ID 208076, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. L. B. Marks, E. D. Yorke, A. Jackson et al., “Use of normal tissue complication probability models in the clinic,” International Journal of Radiation Oncology • Biology • Physics, vol. 76, no. 3, pp. S10–S19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Uhm, “Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group,” Yearbook of Neurology and Neurosurgery, vol. 2010, pp. 118-119, 2010. View at Publisher · View at Google Scholar
  14. C. Wee, E. Kim, I. Kim, I. Kim, N. Kim, and C. Suh, “Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: a multi-institutional study highlighting the mgmt promoter methylation and idh1 gene mutation status,” International Journal of Radiation Oncology • Biology • Physics, vol. 99, no. 2, p. E115, 2017. View at Publisher · View at Google Scholar
  15. P. Tini, P. Pastina, V. Nardone et al., “The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma,” Clinical Neurology and Neurosurgery, vol. 149, pp. 15–21, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Gorlia, M. J. van den Bent, M. E. Hegi et al., “Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3,” The Lancet Oncology, vol. 9, no. 1, pp. 29–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. A. Brandes, A. Tosoni, E. Franceschi et al., “Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation with MGMT promoter methylation status,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1275–1279, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Pedicini, A. Fiorentino, V. Simeon et al., “Clinical radiobiology of glioblastoma multiforme: Estimation of tumor control probability from various radiotherapy fractionation schemes,” Strahlentherapie und Onkologie, vol. 190, no. 10, pp. 925–932, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Tanaka, Y. Ino, K. Nakagawa, M. Tago, and T. Todo, “High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison,” The Lancet Oncology, vol. 6, no. 12, pp. 953–960, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. S. N. Badiyan, S. Markovina, J. R. Simpson et al., “Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide,” International Journal of Radiation Oncology • Biology • Physics, vol. 90, no. 4, pp. 877–885, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Graf, B. Hildebrandt, W. Tilly et al., “Dose-escalated conformal radiotherapy of glioblastomas - Results of a retrospective comparison applying radiation doses of 60 and 70 Gy,” Onkologie, vol. 28, no. 6-7, pp. 325–330, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Massaccesi, M. Ferro, S. Cilla et al., “Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: A phase i dose-escalation study (ISIDE-BT-1),” International Journal of Clinical Oncology, vol. 18, no. 5, pp. 784–791, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. M. D. Piroth, M. Pinkawa, R. Holy et al., “Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas: Results of a prospective phase II study,” Strahlentherapie und Onkologie, vol. 188, no. 4, pp. 334–339, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. R. G. Selker, W. R. Shapiro, P. Burger et al., “The Brain Tumor Cooperative Group NIH Trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine,” Neurosurgery, vol. 51, no. 2, pp. 343–357, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. M. N. Tsao, M. P. Mehta, T. J. Whelan et al., “The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma,” International Journal of Radiation Oncology • Biology • Physics, vol. 63, no. 1, pp. 47–55, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Lacroix, D. Abi-Said, D. R. Fourney et al., “A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival,” Journal of Neurosurgery, vol. 95, no. 2, pp. 190–198, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Sanai, M.-Y. Polley, M. W. McDermott, A. T. Parsa, and M. S. Berger, “An extent of resection threshold for newly diagnosed glioblastomas: clinical article,” Journal of Neurosurgery, vol. 115, no. 1, pp. 3–8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. N. F. Marko, R. J. Weil, J. L. Schroeder, F. F. Lang, D. Suki, and R. E. Sawaya, “Extent of resection of glioblastoma revisited: Personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery,” Journal of Clinical Oncology, vol. 32, no. 8, pp. 774–782, 2014. View at Publisher · View at Google Scholar · View at Scopus